Author

F. Gui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. S. Kibel· 2 shared L. Jia· 2 shared T. Takai· 2 shared T. Tsujino· 2 shared A. D. Choudhury· 1 shared A. Fassl· 1 shared A. Simoneau· 1 shared B. Gui· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. S. Kibel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

F. Gui, B. Jiang, J. Jiang, Z. He, T. Tsujino, T. Takai, S. Arai, C. Pana, J. Koellermann, G. A. Bradshaw, R. Eisert, M. Kalocsay, A. Fassl, S. P. Balk, A. S. Kibel, L. Jia

This paper introduces BSJ-5-63, a PROTAC that degrades CDK12, CDK7, and CDK9, inducing BRCAness and blocking AR signaling to enhance PARP inhibitor sensitivity in prostate cancer.

bioRxiv · Jul 9, 2024 · PreprintCancer Biology

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

X. Li, Y. Pan, Q. Yin, Z. Wang, S. Shan, L. Zhang, J. Yu, Y. Qu, L. Sun, F. Gui, J. Lu, Z. Jing, W. Wu, T. Huang, X. Shi, , X. Wang

This study identifies two broadly neutralizing antibodies against SARS-CoV-2 variants and shows their synergistic neutralization effect, supported by cryo-EM structures.

bioRxiv · May 27, 2022Biochemistry

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

T. Tsujino, T. Takai, K. Hinohara, F. Gui, T. Tsutsumi, X. Bai, C. Miao, C. Feng, B. Gui, S. Sztupinszki, A. Simoneau, N. Xie, L. Fazli, X. Dong, H. Azuma, , L. Jia

This study uses CRISPR screens to identify genetic factors affecting PARP inhibitor sensitivity and resistance in prostate cancer, revealing novel targets and mechanisms.

bioRxiv · Apr 13, 2022 · PreprintCancer Biology